The Benchmark Company Sees Xenotis Acquisition As Good For LeMaitre Vascular
August 19, 2014 at 09:57 AM EDT
In a report published Tuesday, The Benchmark Company analyst Jan Wald reiterated a Buy rating and $11.00 price target on LeMaitre ...